Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Articles

Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

November 10th 2023

Expert oncologist Alex Spira, MD, PhD, FACP, reviews primary results from the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

Dr Spira on the Ongoing Investigation of MYTX-011 in NSCLC

August 15th 2023

Alexander I. Spira, MD, PhD, FACP, discusses a phase 1 study of the antibody-drug conjugate MYTX-011 in patients with non–small cell lung cancer.

Dr Spira on the Ongoing PACIFIC-8 Trial in Unresectable Stage III NSCLC

June 30th 2023

Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.

Dr. Spira on the CNS Activity of Adagrasib in NSCLC

June 23rd 2022

Alexander I. Spira, MD, PhD, FACP, discusses the activity of adagrasib in patients with non–small cell lung cancer and central nervous system metastases.

Dr. Spira on the Results of the TROPION-PanTumor01 Trial in NSCLC

October 13th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the results of the phase 1 TROPION-PanTumor01 trial in non–small cell lung cancer.

Dr. Spira on the Impact of the PACIFIC-R Trial in Unresectable Stage III NSCLC

September 24th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the impact of the PACIFIC-R trial in patients with unresectable stage III non–small cell lung cancer.

NSCLC: Final Thoughts

August 26th 2021

The discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.

NSCLC: Overcoming Challenges

August 26th 2021

Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).

ROS1-Rearranged NSCLC: Updates FromASCO

August 19th 2021

An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.

Preferred Treatment for ALK-Rearranged NSCLC

August 19th 2021

Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).

ALK-Rearranged NSCLC: Updates From ASCO

August 12th 2021

A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).

RET-Fusions in NSCLC: Updates From ASCO

August 12th 2021

An overview of the RET-fusion data updates that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting in non–small cell lung cancer (NSCLC).

Unmet Needs in Non–Small Cell Lung Cancer

August 5th 2021

Unmet needs including strategies to manage brain metastases in non–small cell lung cancer patients are presented.

New Therapies in Non–Small Cell Lung Cancer

August 5th 2021

Alexander Spira, MD, PhD, FACP, highlights emerging targeted agents to treat non–small cell lung cancer with actionable mutations.

Recent FDA-Approvals: MET Exon 14 Mutations in NSCLC

August 5th 2021

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Recent FDA-Approvals: HER2-Mutated NSCLC

August 5th 2021

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

Adverse Events Associated With Mobocertinib

July 29th 2021

Common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors, as well as management strategies are discussed.

Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations

July 29th 2021

Clinical trial data and implications for treating patients with metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations with mobocertinib.

Lung Cancer: Molecular Testing

July 29th 2021

Alexander Spira, MD, PhD, FACP, shares an overview of the molecular testing needed for non–small cell lung cancer and his preferences for testing.

NSCLC: Sotorasib in Practice

July 29th 2021

Experts share their real-world experiences regarding treatment with sotorasib, a new FDA-approved option for KRAS G12C-mutated non–small cell lung cancer (NSCLC).